WntResearch : Presentationen från AGM.

Per Norlén, CEO

AGM, Malmö May 15, 2024

Disclaimer

This company presentation (the "Company Presentation"), which is personal to the recipient, is issued by WntResearch AB (the "Company"). The Company Presentation has been prepared for information purposes only and is not to be relied upon in substitution for the exercise of independent judgement. The Company Presentation may not be reproduced, redistributed, passed on or published, in whole or in part, to any other person for any purpose. Unless otherwise stated, the Company is the source for all data contained in the Company Presentation. Such data is provided as at the date of this Company Presentation and is subject to change without notice. The Company Presentation (together with any further information which may be provided to the addressee) is made available on the condition that it is for use only by the addressee specified above for the sole purpose of evaluating the Company and shall not be passed on to any other person or copied or reproduced, copied, distributed, disclosed or published in whole or part and shall be immediately returned along with any other copies or destroyed at any time at the request of Company.

The Company Presentation is solely for your information and should not be relied upon and shall not confer rights or remedies upon, you or any of your employees, creditors, holders of securities or other equity holders or any other person. No representation or warranty, express or implied, is made by the Company or any of its directors, officers, employees, representatives, advisers or agents or any other person or entity as to the fairness, reasonableness, adequacy, accuracy or completeness of the information, statements or opinions, whichever its source, contained in this document (including any written or oral information made available to any interested party in connection thereto), and no liability whatsoever is accepted by any such person in relation to any such information or opinion. The information contained herein has been prepared to assist interested parties in making their own evaluation of the Company and its credit worthiness and does not purport to be all-inclusive or to contain all information that prospective investors may desire or that may be required to properly evaluate the business, prospects or value of the Company.

The information in this Company Presentation has not been independently verified. No representation or warranty, expressed or implied, is made as to, and no reliance should be placed on, the fairness, accuracy or completeness of the information or opinions contained herein. The Company or any of their respective subsidiaries or affiliates or any of such person's directors, officers or employees, advisers or other representatives, accepts any liability whatsoever (whether in negligence or otherwise) arising, directly or indirectly, from the use of this Company Presentation or otherwise arising in connection therewith. The Company is under no obligation to submit further information. By receiving this Company Presentation and/or attending a presentation concerning the contents hereof you acknowledge that you will be solely responsible for your own assessment of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the Company.

This Company Presentation includes forward-looking statements. All statements other than statements of historical fact included in this Company Presentation, including, without limitation, those regarding the Company's financial position, business strategy, management plans and objectives for future operations are forward-looking statements. These forward- looking statements involve known and unknown risks, uncertainties and other factors, which may cause the Company's actual results, performance, achievements or industry results to be materially different from those expressed or implied by these forward-looking statements. Forward-looking statements speak only as of the date of this Company Presentation and the Company expressly disclaim any obligation or undertaking to release any update of, or revisions to, any forward-looking statements in this Company Presentation as a result of any change in expectations or any change in events, conditions or circumstances on which these forward-looking statements are based. No representation is made that any of these forward-looking statements or forecasts will come to pass or that any forecast result will be achieved.

The goal - reduce mortality from colon cancer

1.1 million diagnosed with colon cancer yearly

The fourth most common form of cancer

5-year survival for non-

metastatic cancer is 71%

About 90 % of deaths

are due to metastases

Five-year survival for

metastatic cancer is 14%

Major medical need to

prevent spread of tumours

WNT5A - an endogenous protein that protects against cancer

WNT5A prevents cancer cells	WNT5A prevents cancer cells	WNT5A reduces the
from detaching from tumours.	from invading healthy tissue.	number of cancer stem cells.

The expression of WNT5A in tumours varies

Low expression	High expression
of WNT5A	of WNT5A
Releases more	Releases fewer
cancer cells	cancer cells

Increases cancer	Decreases
cell's invasiveness	invasiveness

Increases risk of dying	Improves prognosis
from colon cancer	for colon cancer

Low WNT5A correlates with disease progression in colon cancer

Patients with high WNT5A expression had longer cumulative survival*

Restoring WNT5A functions is thought to benefit colon cancer patients

*Dejmek et al. Cancer Res 2005; 65: (20), 2005

Unfortunately, it is not possible to administer WNT5A as a drug due to the complex molecular structure that prevents it from reaching the cancer cells.

Our solution

Foxy-5

A smaller molecule that

mimics WNT5A and reaches cancer cells.

Development

Phase 2 study initiated but paused after promising unexpected findings

Initial Phase 2 study (NeoFox)

127 newly diagnosed patients with stage II/III colon cancer included.

Ad hoc observations based on 110

patients showed very promising and unexpectedly fast effects.

The original NeoFox phase 2 study: ad hoc analysis

Foxy-5

(vs Standard of Care)

		Min 3 weeks				Max 10 weeks

2-year follow upEfficacy assessment

OS/DFS

at 2 years

Diagnosis

Surgery

End of study

ad hoc analysis

The ad hoc observations indicate rapid anti-tumor effects (1/2)

Reduced spread to the tissue surrounding nerves...

	50%
invasion	42%
40%
perineural	30%
with	20%		18%
% patients	10%
21	29	9
	0%
	Control (n=50)	Foxy-5 (n=50)

Less perineural invasion after Foxy-5 treatment (fewer patients had local spread to the tissue surrounding nerves).

The difference between the groups is

statistically significant (p=0.0088).